RARE DISEASE
Oculopharyngeal muscular dystrophy
Oculopharyngeal muscular dystrophy
Oculopharyngeal muscular dystrophy
Synonyms: OPMD
Synonyms: OPMD
Synonyms: OPMD
Drug discovery
3
drugs
With orphan designations
Overview
Oculopharyngeal muscular dystrophy (OPMD) is a rare autosomal dominant disorder caused by PABPN1 gene mutations, characterized by late-onset ptosis, dysphagia, and proximal limb weakness. Symptoms typically emerge in the 40s–50s, progressing slowly. Diagnosis involves genetic testing and clinical evaluation. Management focuses on symptom relief through surgical interventions (e.g., blepharoplasty, cricopharyngeal myotomy) and supportive therapies [1][7][18]. Life expectancy is near-normal with proper care, though complications like aspiration pneumonia pose risks [7][19].
Burden
Physical: Progressive dysphagia increases aspiration and malnutrition risks; mobility loss necessitates assistive devices [4][6][9].
Psychosocial: Chronic fatigue, pain, and social isolation due to visible ptosis and swallowing difficulties [4][13].
Economic: Requires lifelong multidisciplinary care (neurology, ENT, nutrition) [9][19].
Therapies
Surgical: Ptosis correction (frontalis sling), dysphagia management (cricopharyngeal myotomy, Botox injections) [6][8][18].
Supportive: Speech therapy, gastrostomy for severe dysphagia; physiotherapy for limb weakness [6][8][9].
Investigational: RNA replacement, AAV-mediated gene therapy, and trehalose (Phase IIb trial) [3][12][17].
Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare neurological diseases, rare ophthalmic disorders
Research Papers
164 drug discovery papers about Oculopharyngeal muscular dystrophy, with 5 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
164 drug discovery papers about Oculopharyngeal muscular dystrophy, with 5 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-06 | Direct Observationof Structural Unraveling in PABPN1Polyalanine Expansions
Abstract Above-threshold homorepeat expansions promote alternative conformations and irreversible aggregation, driving the malfunction of numerous disease-associated proteins. A detailed understanding of the structural remodeling events in pathogenic mutants enables the identification of key elements determining aberrant structure formation. Here, we describe in high resolution the structural transitions in Poly(A) Binding Protein Nuclear 1 (PABPN1), in which polyalanine expansions beyond a +1 single additional residue cause Oculopharyngeal Muscular Dystrophy (OPMD). PABPN1’s polyalanine tract in its wild-type (containing 10 consecutive alanine residues) and +1 and +8 variants populate alternative polymorphs, with α-helical conformations being increasingly favored and rigid upon expansion. Spontaneous slow unfolding was observed across variants in real time by Nuclear Magnetic Resonance (NMR) spectroscopy, indicating that increased dynamics at the C-terminal end of the polyalanine helix emerges as an early unfolding event associated with functional impairment. Our data help to define key mechanistic features in pathogenic misfunction induced by homorepeat expansions and identify specific structural motifs as potential targets for fragment-based binders to restore protein functionality in polyalanine expansion disorders.
2026-07-28 | Impaired Myogenic Differentiation Is a Shared Feature Across Genetic Myopathies.
There is a shared hallmark of defective differentiation across genetic myopathies, a process that has been extensively described in Duchenne muscular dystrophy and also observed in Emery-Dreifuss muscular dystrophy. In this article, we broaden the discussion on myopathies associated with differentiation defects, examining their implications in less characterized muscle conditions that can have onset in adulthood, including facioscapulohumeral muscular dystrophy (FSHD), oculopharyngeal muscular dystrophy (OPMD), and myotonic dystrophies (DM), as well as myopathies caused by genetic variants in FHL1, GNE, DES, CAPN3, and members of the HNRNP family. Muscle damage can result from injury, exercise, or disease, necessitating a highly coordinated repair process to restore normal strength and function. Resident satellite cells are activated, differentiate, and fuse with the damaged tissue to facilitate this repair. This overview emphasizes the importance of muscle differentiation in the pathogenesis of myopathies with diverse etiologies and a broad range of underlying molecular mechanisms. These insights highlight differentiation as a potential convergent therapeutic target.
2026-06-16 | Distinct roles of IDR and CCD domains control PABPN1 aggregation and enable therapeutic rescue
Abstract PABPN1 is a multifunctional protein whose expression is tightly regulated to maintain cellular homeostasis. PABPN1 dysregulation contributes to both common acquired diseases, such as bladder cancer, and rare inherited disorders, including oculopharyngeal muscular dystrophy (OPMD). In OPMD, PABPN1 forms insoluble aggregates that reduce its functional levels, leading to genome-wide shifts in alternative polyadenylation (APA) at 3′-UTRs and disruption of mRNA metabolism, including nuclear export and translation. OPMD is caused by a short alanine expansion at the N-terminus of PABPN1 within an intrinsically disordered region (IDR) followed by a coiled-coil domain (CCD). How these domains contribute to PABPN1 function and aggregation remains unclear. Here, we show that the N-terminal IDR promotes aggregation and modulates protein-protein interactions with longer IDRs suppressing interaction between PABPN1 and its binding partners. We further demonstrate that the CCD has dual functions: its N-terminal domain dictates PABPN1 stability, whereas its C-terminal domain enhances the PABPN1 interactome. We identified a naturally occurring variant lacking exon 1 encoding the IDR and the CCD N-terminal domain (named trPAB). That variant forms a stable, non-aggregating protein isoform. Interactome analysis and structural modeling indicate improved molecular function by restoring PABPN1 activity, APA profiles, and cellular phenotypes in OPMD and bladder cancer models. Importantly, delivery of trPAB via Adeno-associated viral vector in an OPMD mouse model improves muscle histopathology, supporting its potential as a therapeutic strategy. A mechanistic basis of a novel gene therapy approach for OPMD Top panel: A schematic presentation of three PABPN1 variant functional states. Left: the normal full-length protein interacts with key RNA binding protein (RBP) partners supporting normal cellular function. Middle: A pathogenic full-length alanine-expanded PABPN1 leads to protein aggregation, resulting in limited interactors, dysfunctional complexes and impaired cellular processes. Right: a truncated natural variant (trPAB), not associated with OPMD pathology, shows enhanced stability and reduced aggregation, suggesting a potential protective or “super functional” profile. The bottom panel translates these mechanistic insights into therapeutic strategy. In cell models, expression of trPAB is associated with reduced protein aggregation, restoration of normal cellular function, and improved myogenesis. These effects are recapitulated in a relevant animal model of OPMD, where trPAB treatment leads to decreased aggregation, functional recovery, and reversal of muscle atrophy. Our study supports the rationale for leveraging a stabilized PABPN1 variant as a novel gene therapy approach to counteract aggregation-driven pathology in OPMD. Highlights The central coiled-coil domain (CCD) of PABPN1 has two opposing functions: its N-terminal region stabilizes the protein, while its C-terminal region promotes stability but hampers aggregation. At the N-terminus, an intrinsically disordered region (IDR) acts as a gatekeeper for protein interactions. The alanine tract, including its pathogenic expansion, restricts this interactome, limiting PABPN1 binding capacity. We identified a naturally occurring PABPN1 isoform, trPAB, which lacks exon 1, including the IDR and the N-terminal portion of the CCD. trPAB forms a stable and functional protein and exerts beneficial effects in muscle cells. Functionally, trPAB rescues key cellular phenotypes in bladder cancer cells and reverses nuclear aggregation and muscle atrophy in a mouse model of OPMD.
2026-04-30 | Molecular and therapeutic effects of bioactive compounds-incorporated mucoadhesive buccal patch targeting oral potentially malignant disorders.
Oral potentially malignant disorders (OPMD) are associated with high risk of progression to oral squamous cell carcinoma (OSCC) and remain difficult to manage, due to limited effective localized therapies, underscoring the urgent need for novel, targeted drug delivery systems. A mucoadhesive buccal patch loaded bioactive components such as isotretinoin, bromelain, and limonene (IBL patch) was fabricated and evaluated for its anticancer potential against OPMD-associated OSCC. The cytotoxic study demonstrated that the IBL patch significantly reduced CAL-27 cells viability and found IC50 value around 650 μg/mL, while exhibiting minimal cytotoxicity toward human gingival fibroblast (HGF) cells, indicating selective anticancer activity. In comparison to HGF cells, the IBL patch significantly reduced the migration and invasion of CAL-27 cells. Colony formation assays further confirmed that the IBL patch significantly suppressed the long-term proliferative and clonogenic potential of CAL-27 cells, without affecting HGF cells division. Genotoxicity analysis revealed increased micronucleus formation in CAL-27 cells, suggesting DNA damage-mediated apoptotic induction. Then IBL patch showed molecular effects by suppressing EMT and fibrosis associated TGF-β/SMAD signaling, inhibiting inflammatory (NF-κB), Wnt/β-Catenin pathways and Cytokeratin 17 (CK-17) and restoring epithelial identity through E-Cadherin and CK-18 upregulation. Furthermore, pathway analysis in both monolayer and co-culture inflammatory models demonstrated that the IBL patch effectively suppressed LPS-induced inflammatory markers, including TGF-β, MMP-2, IL-6, and TNF-α expression. Oral acute toxicity testing (OECD 423) confirmed safety of the IBL patch, with no mortality or adverse effects up to 2000 mg/kg (LD₅₀ > 2000 mg/kg; GHS Category 5). Collectively, these findings highlights that the IBL mucoadhesive buccal patch has therapeutic potential against OPMD and controlling pathological epithelial remodeling.
2026-04-02 | Cysteine proteases in oral potentially malignant disorders: Molecular drivers, diagnostic signatures, and therapeutic opportunities.
Cysteine proteases are crucial enzymes regulating protein turnover, apoptosis, signalling, and tissue remodelling, and have emerged as important regulators of the oral epithelial microenvironment with increasing evidence implicating them in the progression of oral potentially malignant disorders (OPMDs) and their potential contribution to malignant transformation toward oral squamous cell carcinoma (OSCC). Dysregulated expression of these enzymes influences key molecular pathways, notably NF-κB, MAPK, protease-activated receptor (PAR) signalling, and apoptotic cascades, although the extent to which individual cysteine proteases act as primary drivers, facilitators of tumour-associated microenvironmental remodelling, or biomarkers of disease progression remains incompletely defined, which govern extracellular matrix remodelling, inflammation, proliferation, migration, and immune evasion, processes associated with malignant progression. Their diagnostic potential is evident through distinct expression patterns in saliva and tissue, suggesting potential utility as adjunct salivary biomarkers for early detection; however, their diagnostic performance relative to established approaches such as toluidine blue staining, autofluorescence imaging, and cytopathological assessment remains to be systematically evaluated. On the therapeutic front, approaches such as selective inhibitors, plant-derived proteases, prodrugs, and multifunctional theranostic agents have been explored experimentally for modulating inflammation, fibrosis, and tumour invasion, while innovative drug delivery strategies aim to increase specificity and reduce systemic toxicity. Nevertheless, most cysteine-protease-targeted interventions remain at preclinical or early translational stages, and clinical validation in oral diseases is currently limited. However, challenges including resistance mechanisms, lack of absolute selectivity, and potential off-target effects necessitate refined computational and experimental strategies for rational inhibitor design. Furthermore, the relative contribution of individual cysteine proteases across different OPMD subtypes remains insufficiently characterized. Future advances lie in validating protease-based biomarkers across diverse populations and embedding them into personalized medicine frameworks.
2026-08-06 | Direct Observationof Structural Unraveling in PABPN1Polyalanine Expansions
Abstract Above-threshold homorepeat expansions promote alternative conformations and irreversible aggregation, driving the malfunction of numerous disease-associated proteins. A detailed understanding of the structural remodeling events in pathogenic mutants enables the identification of key elements determining aberrant structure formation. Here, we describe in high resolution the structural transitions in Poly(A) Binding Protein Nuclear 1 (PABPN1), in which polyalanine expansions beyond a +1 single additional residue cause Oculopharyngeal Muscular Dystrophy (OPMD). PABPN1’s polyalanine tract in its wild-type (containing 10 consecutive alanine residues) and +1 and +8 variants populate alternative polymorphs, with α-helical conformations being increasingly favored and rigid upon expansion. Spontaneous slow unfolding was observed across variants in real time by Nuclear Magnetic Resonance (NMR) spectroscopy, indicating that increased dynamics at the C-terminal end of the polyalanine helix emerges as an early unfolding event associated with functional impairment. Our data help to define key mechanistic features in pathogenic misfunction induced by homorepeat expansions and identify specific structural motifs as potential targets for fragment-based binders to restore protein functionality in polyalanine expansion disorders.
2026-07-28 | Impaired Myogenic Differentiation Is a Shared Feature Across Genetic Myopathies.
There is a shared hallmark of defective differentiation across genetic myopathies, a process that has been extensively described in Duchenne muscular dystrophy and also observed in Emery-Dreifuss muscular dystrophy. In this article, we broaden the discussion on myopathies associated with differentiation defects, examining their implications in less characterized muscle conditions that can have onset in adulthood, including facioscapulohumeral muscular dystrophy (FSHD), oculopharyngeal muscular dystrophy (OPMD), and myotonic dystrophies (DM), as well as myopathies caused by genetic variants in FHL1, GNE, DES, CAPN3, and members of the HNRNP family. Muscle damage can result from injury, exercise, or disease, necessitating a highly coordinated repair process to restore normal strength and function. Resident satellite cells are activated, differentiate, and fuse with the damaged tissue to facilitate this repair. This overview emphasizes the importance of muscle differentiation in the pathogenesis of myopathies with diverse etiologies and a broad range of underlying molecular mechanisms. These insights highlight differentiation as a potential convergent therapeutic target.
2026-06-16 | Distinct roles of IDR and CCD domains control PABPN1 aggregation and enable therapeutic rescue
Abstract PABPN1 is a multifunctional protein whose expression is tightly regulated to maintain cellular homeostasis. PABPN1 dysregulation contributes to both common acquired diseases, such as bladder cancer, and rare inherited disorders, including oculopharyngeal muscular dystrophy (OPMD). In OPMD, PABPN1 forms insoluble aggregates that reduce its functional levels, leading to genome-wide shifts in alternative polyadenylation (APA) at 3′-UTRs and disruption of mRNA metabolism, including nuclear export and translation. OPMD is caused by a short alanine expansion at the N-terminus of PABPN1 within an intrinsically disordered region (IDR) followed by a coiled-coil domain (CCD). How these domains contribute to PABPN1 function and aggregation remains unclear. Here, we show that the N-terminal IDR promotes aggregation and modulates protein-protein interactions with longer IDRs suppressing interaction between PABPN1 and its binding partners. We further demonstrate that the CCD has dual functions: its N-terminal domain dictates PABPN1 stability, whereas its C-terminal domain enhances the PABPN1 interactome. We identified a naturally occurring variant lacking exon 1 encoding the IDR and the CCD N-terminal domain (named trPAB). That variant forms a stable, non-aggregating protein isoform. Interactome analysis and structural modeling indicate improved molecular function by restoring PABPN1 activity, APA profiles, and cellular phenotypes in OPMD and bladder cancer models. Importantly, delivery of trPAB via Adeno-associated viral vector in an OPMD mouse model improves muscle histopathology, supporting its potential as a therapeutic strategy. A mechanistic basis of a novel gene therapy approach for OPMD Top panel: A schematic presentation of three PABPN1 variant functional states. Left: the normal full-length protein interacts with key RNA binding protein (RBP) partners supporting normal cellular function. Middle: A pathogenic full-length alanine-expanded PABPN1 leads to protein aggregation, resulting in limited interactors, dysfunctional complexes and impaired cellular processes. Right: a truncated natural variant (trPAB), not associated with OPMD pathology, shows enhanced stability and reduced aggregation, suggesting a potential protective or “super functional” profile. The bottom panel translates these mechanistic insights into therapeutic strategy. In cell models, expression of trPAB is associated with reduced protein aggregation, restoration of normal cellular function, and improved myogenesis. These effects are recapitulated in a relevant animal model of OPMD, where trPAB treatment leads to decreased aggregation, functional recovery, and reversal of muscle atrophy. Our study supports the rationale for leveraging a stabilized PABPN1 variant as a novel gene therapy approach to counteract aggregation-driven pathology in OPMD. Highlights The central coiled-coil domain (CCD) of PABPN1 has two opposing functions: its N-terminal region stabilizes the protein, while its C-terminal region promotes stability but hampers aggregation. At the N-terminus, an intrinsically disordered region (IDR) acts as a gatekeeper for protein interactions. The alanine tract, including its pathogenic expansion, restricts this interactome, limiting PABPN1 binding capacity. We identified a naturally occurring PABPN1 isoform, trPAB, which lacks exon 1, including the IDR and the N-terminal portion of the CCD. trPAB forms a stable and functional protein and exerts beneficial effects in muscle cells. Functionally, trPAB rescues key cellular phenotypes in bladder cancer cells and reverses nuclear aggregation and muscle atrophy in a mouse model of OPMD.
2026-04-30 | Molecular and therapeutic effects of bioactive compounds-incorporated mucoadhesive buccal patch targeting oral potentially malignant disorders.
Oral potentially malignant disorders (OPMD) are associated with high risk of progression to oral squamous cell carcinoma (OSCC) and remain difficult to manage, due to limited effective localized therapies, underscoring the urgent need for novel, targeted drug delivery systems. A mucoadhesive buccal patch loaded bioactive components such as isotretinoin, bromelain, and limonene (IBL patch) was fabricated and evaluated for its anticancer potential against OPMD-associated OSCC. The cytotoxic study demonstrated that the IBL patch significantly reduced CAL-27 cells viability and found IC50 value around 650 μg/mL, while exhibiting minimal cytotoxicity toward human gingival fibroblast (HGF) cells, indicating selective anticancer activity. In comparison to HGF cells, the IBL patch significantly reduced the migration and invasion of CAL-27 cells. Colony formation assays further confirmed that the IBL patch significantly suppressed the long-term proliferative and clonogenic potential of CAL-27 cells, without affecting HGF cells division. Genotoxicity analysis revealed increased micronucleus formation in CAL-27 cells, suggesting DNA damage-mediated apoptotic induction. Then IBL patch showed molecular effects by suppressing EMT and fibrosis associated TGF-β/SMAD signaling, inhibiting inflammatory (NF-κB), Wnt/β-Catenin pathways and Cytokeratin 17 (CK-17) and restoring epithelial identity through E-Cadherin and CK-18 upregulation. Furthermore, pathway analysis in both monolayer and co-culture inflammatory models demonstrated that the IBL patch effectively suppressed LPS-induced inflammatory markers, including TGF-β, MMP-2, IL-6, and TNF-α expression. Oral acute toxicity testing (OECD 423) confirmed safety of the IBL patch, with no mortality or adverse effects up to 2000 mg/kg (LD₅₀ > 2000 mg/kg; GHS Category 5). Collectively, these findings highlights that the IBL mucoadhesive buccal patch has therapeutic potential against OPMD and controlling pathological epithelial remodeling.
2026-04-02 | Cysteine proteases in oral potentially malignant disorders: Molecular drivers, diagnostic signatures, and therapeutic opportunities.
Cysteine proteases are crucial enzymes regulating protein turnover, apoptosis, signalling, and tissue remodelling, and have emerged as important regulators of the oral epithelial microenvironment with increasing evidence implicating them in the progression of oral potentially malignant disorders (OPMDs) and their potential contribution to malignant transformation toward oral squamous cell carcinoma (OSCC). Dysregulated expression of these enzymes influences key molecular pathways, notably NF-κB, MAPK, protease-activated receptor (PAR) signalling, and apoptotic cascades, although the extent to which individual cysteine proteases act as primary drivers, facilitators of tumour-associated microenvironmental remodelling, or biomarkers of disease progression remains incompletely defined, which govern extracellular matrix remodelling, inflammation, proliferation, migration, and immune evasion, processes associated with malignant progression. Their diagnostic potential is evident through distinct expression patterns in saliva and tissue, suggesting potential utility as adjunct salivary biomarkers for early detection; however, their diagnostic performance relative to established approaches such as toluidine blue staining, autofluorescence imaging, and cytopathological assessment remains to be systematically evaluated. On the therapeutic front, approaches such as selective inhibitors, plant-derived proteases, prodrugs, and multifunctional theranostic agents have been explored experimentally for modulating inflammation, fibrosis, and tumour invasion, while innovative drug delivery strategies aim to increase specificity and reduce systemic toxicity. Nevertheless, most cysteine-protease-targeted interventions remain at preclinical or early translational stages, and clinical validation in oral diseases is currently limited. However, challenges including resistance mechanisms, lack of absolute selectivity, and potential off-target effects necessitate refined computational and experimental strategies for rational inhibitor design. Furthermore, the relative contribution of individual cysteine proteases across different OPMD subtypes remains insufficiently characterized. Future advances lie in validating protease-based biomarkers across diverse populations and embedding them into personalized medicine frameworks.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for Oculopharyngeal muscular dystrophy.
3 orphan drug designations for Oculopharyngeal muscular dystrophy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
genetically modified, non-self replicating Adeno-Associated Virus serotype 9 expressing shRNA to knock down mutant PABP1 as well as a codon optimized, shRNA-insensitive, wildtype PABN1 | gene therapies | FDA | 2018-01-08 | — | Benitec Biopharma Limited |
Genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimized shRNA-insensitive wildtype PABPN1 | gene therapies | EMA | 2017-01-12 | — | Clinipace GmbH |
Trehalose | small molecules | EMA | 2015-05-21 | — | FGK Representative Service GmbH |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.